3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Dermatologic
2
Conditions
Mycosis Fungoides
3
Lymphoma, T-Cell, Cutaneous
3
Neoplasms
2
Lymphoproliferative Disorders
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lymphatic Diseases
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia-Lymphoma, Adult T-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Rituximab
130
Cyclophosphamide
41
Bendamustine Hydrochloride
39
venetoclax
25
fludarabine
25
obinutuzumab
24
Lenalidomide
23
ibrutinib
22
Gemcitabine
22
Vincristine
20
Prednisone
20
tositumomab I-131
19
Doxorubicin
19
plerixafor
14
Dexamethasone
14
Granulocyte Colony-Stimulating Factor
12
pirtobrutinib
11
Brentuximab Vedotin
11
glofitamab
10
tocilizumab
9
pembrolizumab
9
ibritumomab tiuxetan
9
Etoposide
9
Azacitidine
9
polatuzumab vedotin
8
parsaclisib
8
copanlisib
8
acalabrutinib
8
Drug Therapy
8
ublituximab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, Non-Hodgkin
×
cobomarsen
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts
NCT03837457
2020-11-19
PRISM
miRagen Therapeutics, Inc.
Phase 2
Terminated
8 enrolled